This study aimed to determine the pregnancy outcome in women with APS and recurrent pregnancy loss who Phosphoprotein phosphatase
were treated with aspirin alone or aspirin in combination with heparin during the index pregnancy. This prospective non randomized comparative study was conducted at the Department of Obstetrics and Gynecology, Benha University Hospital, and a private centre, since June 2012 till November 2013. After approval of the study protocol by the Local Ethics Committee a written fully informed patients�� consent was obtained. All patients were interviewed about their medical, personal, family, obstetrical and thrombosis history. All patients included in the study met strictly the clinical criteria for diagnosis of Antiphospholipid syndrome which is as follows. One or more episodes of arterial, venous or small vessel thrombosis in any tissue or organ. (a) One or more unexplained deaths Bafilomycin A1 research buy
of morphologically normal foetuses at or after 10?weeks of gestation with normal foetal morphology documented by ultrasound or direct foetal examination. (1) Lupus anticoagulant (LA): In plasma, present on two or more occasions at least 6�C12?weeks apart. All patients (n?=?70) were offered baseline tests including aCL, LA and repeated after 12?weeks before pregnancy and findings noted. All selected patients were in good general health without previous history of Diabetes Mellitus or thyroid dysfunction or cardiac disease. Patients with thrombocytopenia (<100,000/ml), bleeding tendencies, ectopic pregnancy and multiple gestation were excluded from the study. Baseline complete blood picture, routine urine examination, blood sugar, blood Grouping, Bleeding Time, Clotting Time, Prothrombin Time and Activated Partial Thromboplastin Time. Hepatitis B Surface Ag and Hepatitis C Virus screening were offered to all patients and findings noted as soon as they conceived. Anti Xa level were not tested. All selected patients were given routine Folic Acid, Iron and Calcium supplementation orally daily during antenatal period (whether conceived spontaneously or with treatment). All were put on tab aspirin 81?mg/day (Juspirin) daily as soon as gestational sac was visible on ultrasound at around 6?weeks. Then Group A (47 pregnant) were put <a href="http://www.selleckchem.com/products/AP24534.html
">selleck screening library on Inj. Enoxaparin (Clexane) 40?mg subcutaneous once a day when cardiac activity was seen on ultrasound (at around 7�C8?weeks), Inj. Enoxaparin was given either into anterior abdominal wall or anterior aspect of thigh subcutaneously. While Group B (23 pregnant) received aspirin 81?mg/day (Juspirin) daily, no woman experienced any major haemorrhagic event during pregnancy labour or post-partum. Three patients developed mild unexplained vaginal bleeding which settled by expectant management. Discontinuation of medicine was not required due to haemorrhagic problems. Patients were advised to visit fortnightly.